Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) EPS (Basic) (2019 - 2026)

ADC Therapeutics has reported EPS (Basic) over the past 8 years, most recently at -$0.21 for Q1 2026.

  • Quarterly results put EPS (Basic) at -$0.21 for Q1 2026, up 41.67% from a year ago — trailing twelve months through Mar 2026 was -$1.01 (up 12.93% YoY), and the annual figure for FY2021 was -$2.91, up 3.91%.
  • EPS (Basic) reached -$0.21 in Q1 2026 per ADCT's latest filing, up from -$0.3 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $75731.8 in Q1 2022 and bottomed at -$0.6 in Q2 2023.
  • Median EPS (Basic) over the past 5 years was -$0.33 (2025), compared with a mean of $11914.7.
  • The largest annual shift saw EPS (Basic) plummeted 6790.45% in 2024 before it skyrocketed 41.67% in 2026.
  • Over 5 years, EPS (Basic) stood at -$0.0 in 2022, then plummeted by 191318.47% to -$0.57 in 2023, then grew by 26.32% to -$0.42 in 2024, then increased by 28.57% to -$0.3 in 2025, then rose by 30.0% to -$0.21 in 2026.
  • Business Quant data shows EPS (Basic) for ADCT at -$0.21 in Q1 2026, -$0.3 in Q3 2025, and -$0.5 in Q2 2025.